VREX logo

VAREX IMAGING CORP

VREXNASDAQ
πŸ† #2545 by market capEarnings Nov 17US Equity
β€”β€”
Quote unavailable
πŸ””
Track VREX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$782M
Small Cap
πŸ“ˆRevenue Growth (YoY)
5.3%
Slowing
πŸ“ŠGross Margin
34.3%
Moderate
πŸ’΅FCF Margin
1.7%
Thin
βš–οΈP/S Ratio
0.9x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for VREX.

Trading Snapshot

Day Range
β€”
52-Week Range
$9.09 – $18.63
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
42.5M
Next Earnings
2026-11-17

Fundamentals Snapshot

Annual Revenue
$845M
Last Q Revenue
$211M
P/E Ratio
35.4
P/S Ratio
0.9x
EPS (TTM)
$0.52
Dividend Yield
β€”
Dilution (1yr)
+2.5%
VREX logo

VAREX IMAGING CORP

VREX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$845Mβ–² +4.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
34.4%β–² +8.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$28Mβ–Ό βˆ’186.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$19Mβ–Ό βˆ’7.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
41.8Mβ–² +2.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$257Mβ–² +$45M YoY
StockOtter Β· stockotter.space

About VAREX IMAGING CORP

Varex Imaging Corporation (VREX) specializes in the development and production of X-ray imaging components. Its operations are divided into two primary divisions: Medical and Industrial. Within the Medical segment, Varex provides a comprehensive range of X-ray imaging components. These include essential hardware like X-ray tubes, digital detectors, and high-voltage connectors, alongside sophisticated software solutions for image processing, 3D reconstruction, and computer-aided diagnostics. The segment also supplies critical ancillary devices such as collimators, generators, and automatic exposure control mechanisms. These medical products serve a wide spectrum of applications, from general diagnostic imaging like radiography and fluoroscopy, to specialized areas such as mammography, computed tomography (CT), cardiac procedures, dental imaging, and surgical applications. They are also vital for radiation therapy, oncology, and advanced computer-aided detection systems. The Industrial segment focuses on providing X-ray technology for security and industrial inspection. Its offerings include Linatron X-ray accelerators, X-ray tubes, digital detectors, and high-voltage connectors. These components are crucial for diverse applications such as airport security scanning, cargo screening at border crossings, and nondestructive testing across various industries. Varex distributes its products through multiple channels, including direct sales to end-users, partnerships with imaging system Original Equipment Manufacturers (OEMs), independent service providers, and a network of distributors. With a significant global footprint, the company maintains operations across North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Established in 2016, Varex Imaging Corporation is headquartered in Salt Lake City, Utah.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Sell
8 analysts
Strong Buy0
Buy0
Hold5
Sell1
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.